Bloomage Biotechnology Corp Ltd
SSE:688363
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
44.97
80.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bloomage Biotechnology Corp Ltd
Bloomage Biotechnology Corp Ltd
Operating Income
Bloomage Biotechnology Corp Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bloomage Biotechnology Corp Ltd
SSE:688363
|
Operating Income
¥528.1m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Operating Income
-¥8.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Operating Income
¥2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Operating Income
¥1.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Operating Income
¥2.3B
|
CAGR 3-Years
31%
|
CAGR 5-Years
46%
|
CAGR 10-Years
23%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Operating Income
¥4.3B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
11%
|
CAGR 10-Years
42%
|
|
Bloomage Biotechnology Corp Ltd
Glance View
Bloomage Biotechnology Corp. Ltd. engages in the production of hyaluronic acid, sodium hyaluronate bulk drugs, and medical supplements through fermentation. The company is headquartered in Jinan, Shandong and currently employs 3,214 full-time employees. The company went IPO on 2019-11-06. The firm's products include raw material products, medical end products, functional skin care products and functional foods. The raw material products include a series of bioactive products with hyaluronic acid as the core, which are widely used in the fields of drugs, medical devices, cosmetics, functional food and general food. The medical end products are divided into medical beauty and medicine, including ophthalmic viscoelastics, medical lubricants, soft tissue fillers, medical skin protectors and others. The functional skin care products include lotion, cream, facial mask, hand mask and others. The functional foods include hyaluronic acid water, hyaluronic acid food and others.
See Also
What is Bloomage Biotechnology Corp Ltd's Operating Income?
Operating Income
528.1m
CNY
Based on the financial report for Sep 30, 2024, Bloomage Biotechnology Corp Ltd's Operating Income amounts to 528.1m CNY.
What is Bloomage Biotechnology Corp Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-3%
Over the last year, the Operating Income growth was -41%. The average annual Operating Income growth rates for Bloomage Biotechnology Corp Ltd have been -15% over the past three years , -3% over the past five years .
You don't have any saved screeners yet
